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Abstract 
Aims of this study were to investigate the changes in inflammatory regulation as shown by proinflammatory 
cytokines (IL-6) and anti-inflammatory cytokines (IL-10) from patients with systemic inflammatory responses 
syndrome (SIRS) that affect pain intensity changes with the marked increase of critical-care pain observation 
tools (CPOT) and decreased of the pain pressure threshold (PPT). A cross-sectional analysis to compare the 
values of IL-6, IL-10, PPT, and CPOT of SIRS patients and patients without SIRS. Of the 46 patients who were 
the subjects of the study, there were 21 SIRS patients and 25 patients non-SIRS.  Patients with SIRS had higher 
CPOT values than patients without SIRS; CPOT values (3.3 vs. 1.2), significant with p = 0.001 (p < 0.05). The 
PPT scores of patients with SIRS were lower than those without SIRS (4.24 vs. 7.37), significant with p = 0.001 
(p < 0.05).  We conclude that in SIRS patients there is an increase in both proinflammatory (IL-6) and anti-
inflammatory (IL-10) cytokines, but none of those cytokines had a relationship with pain intensity. 
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1. Introduction  
After an inflammatory stimulation by sepsis, there will be an increase of proinflammatory mediators followed 
by an increase of anti-inflammatory mediators [1]. Interleukin-6 is a 22- to 27-kDa glycoprotein secreted by 
many types of cell, such as macrophages, monocytes, eosinophils, hepatocytes, and glial cells. This interleukin 
is one of the earliest and important mediators of induction and control of acute phase protein synthesis and 
releases during pain stimuli, such as trauma, infection, surgery, and burns. After an injury, plasma 
concentrations of IL-6 are detectable within 60 minutes, with a peak between 4 and 6 hours, and it can persist 
for up to 10 days. It is considered the most appropriate marker of the degree of tissue damage during a surgical 
procedure in which excessive and prolonged increase is associated with greater postoperative morbidity.  
Patients with severe sepsis for <48hrs have shown a tight correlation between the elevation of IL-6, the severity 
of the SIRS and subsequent mortality. Interleukin-10 is an 18-kDa nonglycosylated peptide synthesized in 
immune cells and neuroendocrine and neural tissues. It inhibits proinflammatory cytokines, especially TNF, IL-
1, and IL-6, produced by activated macrophages and monocytes, stimulating endogenous production of anti-
inflammatory cytokines. Levels of TNFα and IL-10 were higher in patients with SIRS and MODS, as compared 
to the healthy volunteers [2,3,4]. 
There were reports that a number of patients who survived sepsis developed long-term complications such as 
persistent pain [5], this study attempted to find the cause of chronic pain which usually begins with the 
occurrence of inflammatory pain with inadequate therapy by finding a link between increased proinflammatory 
mediators (IL-6) and increased anti-inflammatory mediators (IL-10) with pain intensity (CPOT) and pain 
excitatory threshold (PPT).  
2. Materials and Method 
2.1. Collection of Samples 
This is an observational study with longitudinal research model. Subjects in this study were patients who 
admitted to the adult intensive care unit of Bintaro Premier Hospital from April 2015 to December 2015. We 
included all subjects who fulfilled inclusion criteria: 1) age >18 years old, 2) indicated to admit ICU, 3) no 
hepatic failure, 4) no renal impairment and excluded subjects with incomplete data and whose families refuse to 
be the subjects of our research. Subjects were categorized into two clinical diagnose: SIRS and nonSIRS as we 
use the SIRS criteria: 1) body temperature >38oC or <36 oC, 2) heart rate >90/minute, 3) respiratory rate > 
20/minute or PaCO2 <32 mmHg, 4) white blood cells count > 12000 cu/mm or < 4000 cu/mm or immature 
neutrophils > 10% as to categorize the subjects.  
All samples who fulfilled inclusion and exclusion criteria and willing to participate in the study and to sign 
informed consent recruited as study samples.  
2.2. Measurement of Il-6, and Il-10 using ELISA 
Examination the plasma levels of IL-6, and IL-10 were using ELISA direct methods. 
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2.3. Classification of pain scale by using CPOT criteria 
We measure the pain level by using CPOT criteria [6] 1) Facial expression (0-2), 2) Body movement (0-2), 3) 
Muscle tension (0-2), 4) or Ventilation compliance or vocalization (0-2). We also measure the pain threshold 
with pressure algometer (PPT) [7] with measurable pressure (kg/m2) at the tendon of extensor carpi radialis [8].  
2.4. Data Analysis 
Data analysis using the SPSS statistics (IBM Corp. Released 2011, version 20 Armonk, NY, US). The measures 
expressed as a mean and standard deviation. We evaluate the association between two qualitative variables with 
Chi Square Test and the association between a qualitative variable and quantitative variable using Mann-
Whitney U-test. We performed correlation test with calculating the determinant (R). A probability value less 
than 5% was considered statistically significant. 
2.5. Ethical Clearance 
Ethical approval for this study obtained from Mochtar Riady Institute for Nanotechnology as well as Bintaro 
Premier Hospital’s ethical board, NO: 02.1403014. We obtained written informed consent from all patient’s 
family. 
3. Results 
Of the 205 adult patients admitted during the study period, there were 25 SIRS patients who met the inclusion 
criteria; four patients excluded for rejecting and lacking the data.  Of the group of patients, non-SIRS 25 patients 
were willing to be the subjects of the study, thus during the collection period, we obtained 46 patients as 
research subjects with 21 patients SIRS (45.7%) and 25 patients, nonSIRS (54.3%). We should consider the 
population of this study because there are age differences in the two sample groups. 
Table 1: Characteristics of Subjects 
 
Characteristics 
SIRS  
p 
Yes (n=21) 
Mean±SD 
No (n=25) 
Mean±SD 
Age (years) 57.9±11.1 51.0±4.8 0.014 
BMI (kg/m2) 25.06±4.90 26.10±5.59 0.511 
MAP 87.56±18.10 93.53±8.69 0.177 
HR (x/minute) 104.2±21.8 74.5±11.5 <0.001 
RR (x/minute) 23.8±8.0 16.5±2.3 0.001 
pCO2 (mmHg) 36.1±8.2 36.3±4.9 0.943 
WBC (/mm3) 16743.33±9145.02 5956.00±1668.85 <0.001 
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Measurements of the pain scale were using the CPOT [1], while measurements of the pain threshold were using 
algometer in assessing PPT [9]. Both of these measurements were done directly by the researcher to avoid the 
measurement bias. The CPOT value in SIRS patients was higher than in the non-SIRS group (3.3 versus 1.2: p = 
0.001). The mean value of PPT in the SIRS group was significantly lower than in the non-SIRS group (4.24 
versus 7.37: p = 0.001). From these two measures, it concluded that SIRS patients have higher pain with a lower 
pain threshold. Furthermore, from these findings, it is necessary to analyze the factors that cause it.  
Table 2: Pain Score (CPOT), Pain Threshold (PPT), and PGE2 
 
Parameters 
SIRS  
p 
Yes (n=21) 
Mean±SD 
No (n=25) 
Mean±SD 
PPT (kg) 4.24±1.26 7.37±1.31 0.001 
CPOT    3.3±1.8 12±0.6 0.001 
 
SIRS is a spectacular inflammatory reaction that is also known as a cytokine storm, the release of various 
cytokines into the blood circulation [10]. The first phase characterized by an increase in TNF-α, IL-1β, and IL-6. 
While the second phase is hypo-inflammation and characterized by increased concentrations of IL-10 and some 
other anti-inflammatory cytokines.  While the next step is a balance between proinflammation and anti-
inflammatory [11,12]. To maintain homeostasis, levels of anti-inflammatory cytokines such as interleukin-10 
also increased when there was an increase in proinflammatory cytokines [13,14, 15]. Although both 
proinflammatory and anti-inflammatory levels were significantly increased (IL-6: 129.18 versus 9.70, p <0.001 
and IL-10: 114.40 versus 12.03, p <0.001), it turned out that when traced in SIRS patients, the proinflammatory 
cytokines are more dominant than anti-inflammatory ones. This shown by the difference in the ratio of IL-6 / IL-
10 levels in the SIRS group significantly higher than in the no-SIRS group (5.04 versus 0.64, p <0.001). The 
explanation of this is that the cause of SIRS with all its manifestations is due to the dominance of the higher 
inflammatory mediators than the anti-inflammatory mediators [16]. Or it can also be said SIRS occurs due to the 
failure of suppression from the anti-inflammatory mediator. (Table 3).  
Table 3: Comparison of inflammatory status between the two groups 
 
Inflammatory status 
SIRS  
p 
Yes (n=21) 
Mean±SD 
No (n=25) 
Mean±SD 
IL-6 (pg/mL) 129.18±110.51 9.70±29.17 <0.001 
IL-10 (pg/mL) 114.40±181.32 12.03±27.05 <0.001 
IL-6/IL-10 ratio 5.04±7.49 0.64±1.51 <0.001 
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Pain that occurs in patients with SIRS in the ICU is an inflammatory pain caused by an increase in inflammatory 
mediators. This pain is a pain that is adaptive and protective with a decrease in the threshold of excitatory pain 
[17]. The reduced limit of excitatory pain caused by the influence of mediators on nociceptors resulting in 
increased excitability of outer nociceptor membrane [18]. The arachidonic acid present in the cell wall 
phospholipid produced when the injury occurs, and the cascade process becomes prostaglandin, prostacyclin, 
and thromboxane and causes inflammation and pain. This process is the enzyme cyclooxygenase (COX-1) 
which is the essential protein that causes changes in arachidonic acid into protective compounds and COX-2 
enzymes that produce prostaglandins with inflammatory effects, including pain [19].  Although both 
proinflammatory (IL-6) and anti-inflammatory (IL-10) inflammatory mediators increased in the SIRS group, 
none were correlated with decreased pain threshold value (PPT) or with increased pain intensity (CPOT) in this 
study (Table 6 and 7). 
Table 6: Correlation between PPT, IL-6, IL-10, and IL-6/IL-10 ratio 
 Bivariate Partial 
R p R p 
PPT vs IL-6 -0.569 <0.001 -0.244 0.069 
PPT vs IL-10 -0.515 <0.001 -0.161 0.148 
PPT vs IL-6/IL-10 -0.480 <0.001 -0.046 0.381 
 
Table 7: Correlation between CPOT, IL-6, IL-10, and IL-6/IL-10 ratio 
 Bivariate Partial 
R p R p 
CPOT vs IL-6 0.727 <0.001 0.120 0.217 
CPOT vs IL-10 0.607 <0.001 0.157 0.152 
CPOT vs IL-6/IL-10 0.590 <0.001 0.024 0.438 
 
4. Discussion 
From this study, we suspect that SIRS which is the embryo of sepsis as one of the causes of post sepsis chronic 
pain as we found the hypersensitivity of pain characterized by a decrease in PPT value and an increase of 
CPOT. 
This study showed that in SIRS patients increased proinflammatory cytokines (IL-6) and anti-inflammatory 
cytokines (IL-10) differed in levels. Critically ill patients in the intensive care unit (ICU) almost always feel 
pain during treatment. In a study of 158 patients who had been treated in ICU with mechanical ventilation, 47% 
reported feeling anxious and afraid of their actions, and 36% still remembered the pain they experienced [20]. In 
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another study conducted by interview, 64% of ICU cardiac surgery patients reported moderate to severe pain 
[21]. A significant problem is a pain that persists after the patient leaves the ICU. Of these variables, statistically 
significant causes of the post-treatment pain in ICU were age and sepsis [22].  
Pain treatment for ICU patients can be done by decreasing the effects of inflammatory mediators from pain by 
using anti-inflammatory drugs as an adjunctive therapy in other analgesics drugs [23].  With precaution and to 
avoid the contraindications such as renal insufficiency, active peptic ulcer, coagulation disorders [24]. To 
prevent the occurrence of pain hypersensitivity due to both peripheral and central sensitization, ICU physicians 
may use the multimodal analgesia [25]. Due to the presence of inflammatory dysregulation in SIRS patients, it is 
important to consider inflammation with anti-inflammatory drugs so that the inflammatory process becomes 
controlled. Although indirect correlated with the occurrence of pain hypersensitivity, increases in both 
proinflammatory mediators and anti-inflammatory mediators should be suspected to play a role in the 
occurrence of hypersensitivity of pain through other mechanisms or other compounds. Therefore it is necessary 
to do further analysis to find it. 
5. Conclusion 
Systemic inflammation characterized by SIRS results in changes in the levels of proinflammatory cytokines (IL-
6).  Accompanied by shifts in the levels of anti-inflammatory cytokines (IL-10) that will decrease excitatory 
pain threshold (PPT) due to peripheral and central sensitization resulting in increased pain (CPOT) on SIRS 
patients in ICU.  Therefore, to reduce pain hypersensitivity in patients with SIRS, inflammatory controls, such 
as with anti-inflammatory administration (especially COX-2 inhibitors) or administration of antihyperalgesic 
drugs are warranted. For the management of sepsis which is the most complicated form of SIRS in the ICU, in 
addition to efforts to eradicate germs with adequate antibiotics, hemodynamic control or other vital body 
support, the equally important effort according to the results of this study is to control Inflammatory and surely 
overcome the resulting hyperalgesia.  Options for the administration of antiinflammation that may control the 
inflammatory dysregulation. 
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